Triazolopyridine compounds
A technology of compounds and oxides, applied in WO 20, the preparation of pharmaceutical compositions for treating or preventing diseases, and the field of intermediate compounds for the preparation of said compounds, which can solve problems such as low hydrolytic stability
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 011
[1147]
[1148]To a stirred suspension of Int3.4 (150 mg) in toluene (3.5 mL) and NMP (0.5 mL), was added 4-bromo- N , N - Diethyl-3-methoxybenzamide (237 mg), Pd 2 dba 3 (19 mg) and rac-BINAP (26 mg). The flask was degassed twice and backfilled with argon. The mixture was stirred at room temperature for 5 minutes. Cesium carbonate (405 mg) was added, the flask was degassed twice and backfilled with argon, and the mixture was heated to reflux for 20 h. Water was added, and the reaction mixture was extracted with ethyl acetate. The organic phase was washed with saturated sodium chloride solution, dried (sodium sulfate) and the solvent was removed in vacuo. Chromatography on silica gel gave a solid which was triturated with cyclohexane to give 27 mg of the title compound.
[1149]
[1150] Starting from intermediate Int3.4, examples 01.2 to 01.5 were prepared analogously to the preparation procedure of example 01.1.
[1151] Example 01.2
Embodiment 012
[1153]
[1154]
[1155] Starting materials: intermediate Int3.4; 4-bromo-3-methoxybenzonitrile.
[1156] Example 01.3
Embodiment 013
[1158]
[1159]
[1160] Starting materials: intermediate Int3.4; 1-Bromo-2-ethoxy-4-fluorobenzene.
[1161] Example 01.4
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 
PatSnap Eureka turns technology decisions into work you can execute. Powered by our Innovation Knowledge Graph, it runs expert workflows across engineering, life sciences, materials and intellectual property. Get your review-ready output in minutes.
